Form 4: Xeris Biopharma Director John Johnson Receives 50,000 Restricted Stock Units

Xeris Biopharma Holdings, Inc. Director John Johnson was granted 50,000 restricted stock units, aligning his interests with shareholders and vesting by June 2026.

Summary

• John Johnson, a Director of Xeris Biopharma Holdings, Inc. (XERS), acquired 50,000 shares of common stock on June 4, 2025.
• These shares were granted as a restricted stock unit (RSU) award under the Company's 2018 Stock Option and Incentive Plan.
• Each RSU represents a contingent right to receive one share of the company's common stock.
• The shares will vest in full upon the earlier of June 4, 2026, or the date of the Company's next annual meeting of stockholders.
• Following this transaction, John Johnson beneficially owns 940,983 shares of Xeris Biopharma Holdings, Inc. common stock.

Sentiment

Score: 7

Explanation: The grant of restricted stock units to a director is generally a positive sign of alignment between management and shareholder interests, and a standard practice for executive compensation. While it involves potential future dilution, the immediate impact is neutral to slightly positive due to incentive alignment.

Positives

• The grant of restricted stock units to a director aligns management's interests with those of shareholders, incentivizing long-term performance.
• The award is part of the company's established 2018 Stock Option and Incentive Plan, indicating a structured approach to executive compensation.

Negatives

• The issuance of new shares, even as restricted stock units, can lead to a slight dilution of existing shareholder equity upon vesting.

Risks

• The value of the restricted stock units is contingent on the future performance of Xeris Biopharma's common stock, meaning the actual value realized by the director could be lower if the stock price declines.
• The vesting schedule ties the director's compensation to continued service, but also means the shares are not immediately liquid.

Industry Context

This Form 4 filing details an individual insider transaction, which is a routine disclosure for publicly traded companies. It does not provide broad industry trends but reflects standard compensation practices within the biopharmaceutical sector to incentivize and retain key personnel.

Related Party Transactions

• The acquisition of 50,000 restricted stock units by Director John Johnson from Xeris Biopharma Holdings, Inc. constitutes a related party transaction as it involves compensation from the company to a member of its board of directors.

Stakeholder Impact

• Shareholders: Potential for minor future dilution upon vesting of the RSUs, but also improved alignment of director's interests with long-term shareholder value.
• Employees: No direct impact on general employees mentioned, but reflects the company's compensation strategy for key personnel.

Next Steps

• Vesting of the 50,000 restricted stock units upon the earlier of June 4, 2026, or the date of the Company's next annual meeting of stockholders.

Key Dates

Keywords

Xeris Biopharma Holdings, XERS, Form 4, SEC Filing, Insider Transaction, Restricted Stock Units, RSU, Director Compensation, Equity Award, Stock Option and Incentive Plan, John Johnson